You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

478 Results
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Document
Regimen
Intent: Adjuvant, Curative
Funding:
Exceptional Access Program
    daBRAfenib - For the adjuvant treatment of resected Stage III cutaneous melanoma, based on criteria
Exceptional Access Program
    trametinib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec.
Recommandations fondées sur les données probantes de ContrôleCancerColorectal, le programme ontarien de dépistage du cancer colorectal. Aussi...
Blog post
Nausea and vomiting due to cancer treatment are two of the most dreaded side effects of chemotherapy for many patients and their care providers. The...
Jul 2019

Pages